An update on emerging drugs for the treatment of hypercholesterolemia

Research output: Contribution to journalReview ArticleResearchpeer-review

5 Citations (Scopus)


Introduction: Elevated levels of low-density lipoprotein (LDL) cholesterol have been unequivocally demonstrated to play a causal role in atherosclerotic cardiovascular disease. The last thirty years have witnessed a generation of clinical trials that have demonstrated a reduction in cardiovascular risk with the use of increasing intensive lipid lowering regimens involving statin therapy in combination with other agents. However, many patients fail to achieve treatment mandated LDL cholesterol goals. This highlights the need to develop additional approaches to lower LDL cholesterol levels. Areas covered: (i) Contemporary data highlighting the atherogenicity of LDL cholesterol and cardiovascular benefits of current lipid lowering therapies. (ii) Importance of statin intolerance and inability to achieve LDL cholesterol goals in driving ongoing cardiovascular risk. (iii) Emergence of new therapeutic agents designed to achieve more effective lowering of LDL cholesterol. Expert opinion: Effective lowering of LDL cholesterol plays a critical role in approaches to the prevention of cardiovascular disease. A greater number of patients will require combinations of agents to achieve optimal lipid control. Accordingly, new agents will be required to provide sufficient choice for patients at high cardiovascular risk.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalExpert Opinion on Emerging Drugs
Issue number4
Publication statusPublished - 2021


  • cardiovascular disease
  • cardiovascular prevention
  • Hypercholesterolemia
  • lipid lowering agents
  • risk factor

Cite this